Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function
Status:
Completed
Trial end date:
2017-10-25
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the pharmacokinetics of entospletinib
(ENTO) and/or its metabolites (if applicable) in participants with impaired hepatic function
(stratified by smoking status, as appropriate) relative to matched, healthy controls.